AKT1 is a gene that encodes a protein called AKT1 kinase, one of the most important signaling molecules in human cells. It sits at a crossroads where signals about growth, metabolism, and survival converge, and when it malfunctions, the consequences range from cancer to overgrowth disorders to cardiovascular disease. The gene’s reach across so many organ systems makes it one of the most studied targets in modern medicine, and one of the hardest to treat when things go wrong.
What AKT1 Does in a Healthy Cell
Think of AKT1 as a relay switch. When the cell receives signals from outside, like growth factors or insulin, those signals travel through a chain of molecular events until they reach AKT1. Once activated, AKT1 flips on dozens of downstream processes: it tells the cell to grow, to divide, to take in glucose, and to resist signals that would otherwise trigger cell death. It also helps balance whether stem cells renew themselves or mature into specialized tissue, though the outcome depends heavily on the cell type and context.
In its resting state, AKT1 keeps itself switched off through a built-in brake. A region of the protein folds over the active site and blocks it. Activation requires the cell to remove that brake through a process involving the addition of chemical tags called phosphate groups at specific locations on the protein. The main activation site is at a position called Thr308, but full activation typically requires a second tag at Ser473. These two modifications cause the protein to unfold into its active shape.
Researchers have found that AKT1 can actually reach its active state through more than one route. The classic pathway involves Ser473, which triggers a change that lifts the internal brake. But tagging two nearby sites simultaneously, Ser477 and Thr479, produces a different active shape entirely, one that weakens AKT1’s attachment to the membrane lipids it normally needs to function.1Cell. Comprehensive analysis of AKT1 activation by phosphorylation This means cells have more than one way to dial AKT1 activity up or down, which helps explain why the protein shows up in so many different biological processes.
Three Versions of AKT and Why AKT1 Stands Out
Humans carry three closely related AKT genes: AKT1, AKT2, and AKT3. All three produce proteins with similar structures and overlapping abilities, but they are not interchangeable. Studies in mice missing individual versions have shown that each isoform has distinct roles. AKT1 knockout mice tend to be smaller overall, pointing to its importance in body-wide growth. AKT2 knockouts develop problems with blood sugar regulation resembling diabetes. AKT3 knockouts have reduced brain size.2PubMed Central. The Akt kinases: isoform specificity in metabolism and cancer
The differences go deeper than growth and metabolism. In the inner ear, for example, all three isoforms are present, but only AKT2 and AKT3 protect the delicate hair cells that detect sound from toxic damage. AKT1 does not contribute to that protective role, yet mice missing AKT1 along with one of the other isoforms still develop hearing loss, suggesting AKT1 supports normal hearing through a different mechanism.3PubMed Central. All Akt isoforms (Akt1, Akt2, Akt3) are involved in normal hearing, but only Akt2 and Akt3 are involved in auditory hair cell survival in the mammalian inner ear These distinctions matter for drug development, because a therapy that shuts down all three isoforms will have broader side effects than one that selectively targets only the isoform driving a particular disease.
AKT1 Mutations and Cancer
Because AKT1 promotes cell survival and growth, mutations that lock it into its “on” position can push cells toward cancer. The most well-characterized cancer-linked mutation is called E17K, a single letter change in the gene’s DNA that swaps one amino acid for another at position 17 of the protein. This mutation causes AKT1 to activate without waiting for the normal upstream signals, essentially removing the requirement for an external green light.
E17K mutations turn up across several cancer types, including breast, ovarian, endometrial, and colorectal cancers. In breast cancer specifically, the mutation is found in a meaningful fraction of hormone-receptor-positive tumors. Liquid biopsy approaches, which detect tumor DNA fragments circulating in the blood, can now pick up E17K mutations alongside other pathway alterations. One study using a digital PCR assay found the AKT1 E17K mutation co-occurring with an estrogen receptor mutation in about 14% of plasma samples from breast cancer patients.4The Journal of Liquid Biopsy. Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR Blood-based testing for these mutations is becoming increasingly reliable when there is enough tumor DNA in circulation; agreement between blood and tissue results reaches 100% for AKT1 when the circulating tumor fraction is above 1%, though accuracy drops when levels are very low.5PubMed Central. Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations
Proteus Syndrome and Mosaic Overgrowth
One of the most dramatic consequences of an AKT1 mutation occurs not in cancer but in a rare developmental condition called Proteus syndrome. This is the disorder believed to have affected Joseph Merrick, historically known as “the Elephant Man.” Proteus syndrome causes asymmetric, progressive overgrowth of bones, skin, and connective tissue, along with a heightened risk of certain tumors.
In 2011, researchers identified the cause: the same E17K mutation seen in cancers, but arising spontaneously during embryonic development and present in only some of the body’s cells. Of 29 patients studied, 26 carried this mosaic AKT1 mutation.6PubMed Central. A mosaic activating mutation in AKT1 associated with the Proteus syndrome Because the mutation occurs after conception and only affects a subset of cells, the overgrowth is patchy rather than uniform across the body. The mutation is not inherited from parents and cannot be passed to children in the usual way, since it exists in only a fraction of the affected person’s cells.
Proteus syndrome shares clinical overlap with another group of overgrowth conditions caused by mutations in PIK3CA, the gene encoding the enzyme directly upstream of AKT in the same signaling chain. These conditions, collectively called PIK3CA-related overgrowth spectrum, produce similar but distinguishable patterns of tissue enlargement. Both groups carry an increased risk of blood clots, highlighting how activation of this shared signaling pathway affects the vascular system as well as tissue growth.7PubMed Central. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome
The discovery of the AKT1 mutation in Proteus syndrome opened the door to targeted treatment. Miransertib, an AKT inhibitor originally developed for cancer, was tested in a pilot study of adults and children with the condition. At a dose roughly one-seventh of what oncology patients receive, the drug cut phosphorylated AKT levels in affected tissues by half in five of six participants. The investigators also observed a reduction in pain and some shrinkage of overgrown tissue in children, offering the first real therapeutic hope for a condition that previously had none.8PubMed Central. Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
Blood Pressure and Blood Vessel Repair
AKT1 plays a surprisingly central role in the cardiovascular system, largely through its control of nitric oxide production. Nitric oxide is the molecule that tells blood vessel walls to relax, and AKT1 activates the enzyme that produces it. When researchers knocked out AKT1 specifically in the endothelial cells lining blood vessels, the animals showed reduced nitric oxide output, stiffer arteries, and consistently elevated blood pressure throughout the day.9PubMed Central. Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis
The cardiovascular consequences extend beyond blood pressure. AKT1 is also required for the growth of new blood vessels after injury. In animal models of restricted blood flow to a limb, mice lacking endothelial AKT1 showed impaired recovery because they could not form new arterial connections to bypass the blockage.10PubMed. Regulation of arterial blood pressure by Akt1-dependent vascular relaxation AKT1 is also needed for the normal migration of endothelial cells and fibroblasts toward chemical signals, a key step in wound healing and tissue remodeling.11Journal of Clinical Investigation. Akt1 in the cardiovascular system: friend or foe? This creates an interesting tension: too much AKT1 activity drives tumor growth, but too little leaves the cardiovascular system unable to maintain healthy blood pressure or recover from vascular injuries.
Insulin Sensitivity and Glucose Handling
When insulin binds to its receptor on a cell’s surface, the signal passes through AKT1 to trigger glucose uptake and storage. This makes AKT1 a direct participant in how the body manages blood sugar. Recent research has identified a protein called TSC22D4 that physically binds to AKT1 and acts as a kind of environmental sensor. During fasting, TSC22D4 keeps AKT1 activity dialed down, which prevents the cell from pulling in glucose when insulin levels are low. This partnership actually improves insulin sensitivity: in mice, restoring the TSC22D4-AKT1 interaction in the liver led to better glucose handling.12PubMed Central. TSC22D4 interacts with Akt1 to regulate glucose metabolism
The metabolic role of AKT1 is closely tied to its isoform AKT2, which is the dominant player in insulin-responsive tissues like fat and muscle. But AKT1’s contribution in the liver and during development should not be overlooked. Mice completely lacking AKT1 show growth retardation that begins before birth, with their placentas displaying reduced blood vessel formation and a near-complete loss of certain nutrient-storing cells. These placental defects likely contribute to fetal growth impairment.13PubMed. Protein kinase B alpha/Akt1 regulates placental development and fetal growth
AKT1, Cannabis, and Psychosis Risk
One of the more unexpected chapters in AKT1 research involves the brain and mental health. Genetic variation in the AKT1 gene appears to influence how vulnerable a person is to the psychosis-promoting effects of cannabis. A specific variant at a location called rs2494732 does not, on its own, increase the risk of developing a psychotic disorder. But it significantly modifies what happens when someone with that variant uses cannabis.14PubMed Central. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder
In one study, people carrying two copies of the C version of this variant who had used cannabis were more than twice as likely to have a psychotic disorder compared to cannabis users carrying two copies of the T version. Among daily cannabis users, the gap widened dramatically: C/C carriers had roughly seven times the odds of psychosis compared to T/T carriers.15Biological Psychiatry. AKT1 and Cannabinoid Interaction in Psychosis This is a gene-environment interaction, meaning the genetic variant is harmless in the absence of heavy cannabis exposure, and cannabis use is lower risk for people without the variant. The combination is what matters.
The biological rationale is plausible. Cannabis affects dopamine signaling in the brain, and AKT1 sits in a signaling chain that modulates dopamine receptor sensitivity. A less efficient version of AKT1 could leave certain brain circuits more vulnerable to the dopamine surges that cannabis can trigger.
Immune Regulation and Inflammation
AKT1 helps calibrate how aggressively the immune system responds to threats. In macrophages, the immune cells that serve as the body’s first responders to infection, AKT1 controls the levels of several small regulatory molecules called microRNAs. When macrophages encounter bacterial components, AKT1 activation adjusts microRNA levels in a way that keeps the inflammatory response in check. Without AKT1, macrophages react more aggressively to bacterial signals and fail to develop tolerance after repeated exposure.16Immunity. Akt1 Regulates Macrophage Response to Lipopolysaccharide by Regulating MicroRNA Expression
Endotoxin tolerance is the process by which immune cells become less reactive after prolonged stimulation, a protective mechanism that prevents the body from destroying its own tissues during a sustained infection. Mice lacking AKT1 failed to develop this tolerance, suggesting their immune systems could not downshift once activated. The practical implication is that AKT1 may be part of what separates a proportionate immune response from the kind of runaway inflammation seen in sepsis.
Cellular Aging and Oxidative Stress
AKT1’s relationship with cellular aging is genuinely paradoxical. On one hand, AKT1 activation can push cells into a state called senescence, where they stop dividing permanently. This happens because active AKT1 ramps up the cell’s oxygen consumption, producing damaging reactive oxygen species as a byproduct. At the same time, AKT1 suppresses the cell’s built-in antioxidant defenses by blocking protective factors downstream. The combined effect is a surge in oxidative stress that triggers senescence.17PubMed Central. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis
On the other hand, cells completely lacking AKT1 are also vulnerable to premature aging under certain conditions. When AKT1-deficient mouse cells were exposed to ultraviolet light, they rapidly became senescent due to a spike in reactive oxygen species that they could not manage. Restoring AKT1 expression reversed the problem.18PubMed. UV light induces premature senescence in Akt1-null mouse embryonic fibroblasts by increasing intracellular levels of ROS So both too much and too little AKT1 can accelerate aging, through related but distinct oxidative stress mechanisms.
This has real-world relevance in conditions like osteoarthritis. In mice, sustained AKT1 pathway activation in the cartilage cells of joints caused those cells to become senescent and secrete inflammatory enzymes that broke down the surrounding tissue, producing progressive joint degeneration that worsened with age. An antioxidant compound slowed this process by mopping up the excess reactive oxygen species.19Bone Research. Sustained Akt signaling in articular chondrocytes causes osteoarthritis via oxidative stress-induced senescence in mice
Drugs That Target AKT1 in Cancer
The clearest therapeutic success story so far is capivasertib, an oral drug that blocks all three AKT isoforms and was approved for use in combination with the hormone therapy fulvestrant for advanced breast cancer. In the pivotal trial, patients whose tumors carried alterations in the AKT pathway saw their median time without disease progression roughly double, from about 3 months with fulvestrant alone to about 7 months with the combination.20PubMed Central. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer Capivasertib is the first AKT inhibitor to reach regulatory approval, and its success validated years of work on the pathway.21PubMed. Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
For patients specifically carrying the AKT1 E17K mutation, earlier trials of capivasertib in combination with fulvestrant showed overall response rates of about a third among those who had already tried fulvestrant, with roughly half achieving disease control lasting at least six months.22Clinical Cancer Research. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer These are meaningful numbers for patients who have run out of standard options, though the responses are rarely permanent.
Why Tumors Fight Back Against AKT Inhibitors
One of the frustrations of targeting the AKT pathway is that cancer cells are remarkably good at finding workarounds. AKT normally keeps a tight lid on the production of several growth factor receptors on the cell surface. When a drug shuts AKT down, that lid comes off, and the cell rapidly increases its production of receptors that can restart growth signaling through alternative routes.23Cancer Discovery. Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
This feedback loop operates through transcription factors that AKT normally suppresses. When AKT is inhibited, those factors become active and switch on genes for receptors that feed back into the same growth pathway, or activate entirely different pathways. In breast cancers driven by the HER2 receptor, chronic treatment with drugs blocking the HER2-AKT axis can trigger activation of an alternative signaling cascade that stabilizes a protein promoting cell proliferation.24PubMed Central. Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop The practical consequence is that AKT inhibitors tend to work best when paired with drugs that block these escape routes simultaneously, which is why combination therapy is the standard approach rather than single-agent treatment.
How Viruses Exploit AKT1
Viruses are opportunistic by nature, and many have evolved to hijack the AKT signaling pathway to create a more hospitable environment inside the cells they infect. Herpesviruses, for instance, produce multiple proteins that activate the AKT pathway at different stages of their life cycle, using it to keep infected cells alive, support viral replication, and maintain the latent infections that allow these viruses to persist for a lifetime.25PubMed Central. The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside
The relationship extends beyond herpesviruses. Research on a group of viruses called paramyxoviruses found that blocking AKT1 with either chemical inhibitors or genetic silencing reduced viral replication. The same was true for vesicular stomatitis virus, a member of a different viral family, suggesting that dependence on AKT may be a widespread feature of certain virus types.26PubMed Central. Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses Even Ebola virus activates the AKT pathway during cell entry; blocking it with inhibitors significantly reduced infection at a very early stage of the viral life cycle.27PLoS Pathogens. Phosphoinositide-3 Kinase-Akt Pathway Controls Cellular Entry of Ebola Virus
This raises an intriguing therapeutic possibility. If AKT inhibitors developed for cancer also suppress viral replication, they could theoretically be repurposed as antiviral agents. The challenge, as with cancer treatment, is that AKT1 does so many essential things in healthy cells that blocking it broadly comes with real costs. Any antiviral application would need to be targeted carefully to avoid trading one problem for another.